Tremendous news. XP has long been anticipated as a target indication.
Now that the company is self funding, it's great to see an accelerated clinical program.
XP is a horrid disease. No current treatment, and fatal.
If Scenesse works in XP, you'd not expect any payor would resist the treatment in the way some have in EPP.
First results due in 2021.
Tremendous news. XP has long been anticipated as a target...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.58 |
Change
-0.930(6.00%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $4.173M | 285.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.58 | 1486 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |